Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.41 Insider Own0.11% Shs Outstand5.80M Perf Week-29.15%
Market Cap4.36M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.79M Perf Month-29.81%
Income-38.52M PEG- EPS next Q- Inst Own12.27% Short Float0.42% Perf Quarter-49.60%
Sales0.00M P/S- EPS this Y- Inst Trans-39.84% Short Ratio0.16 Perf Half Y-64.41%
Book/sh1.06 P/B0.71 EPS next Y- ROA-117.64% Short Interest0.02M Perf Year-90.52%
Cash/sh2.26 P/C0.33 EPS next 5Y- ROE-172.45% 52W Range0.75 - 8.92 Perf YTD-76.82%
Dividend Est.- P/FCF- EPS past 5Y63.67% ROI-509.34% 52W High-91.58% Beta1.85
Dividend TTM- Quick Ratio5.99 Sales past 5Y0.00% Gross Margin- 52W Low0.13% ATR (14)0.11
Dividend Ex-Date- Current Ratio5.99 EPS Y/Y TTM30.60% Oper. Margin0.00% RSI (14)26.53 Volatility16.21% 10.22%
Employees22 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price22.00
Option/ShortNo / No LT Debt/Eq0.01 EPS Q/Q83.83% Payout- Rel Volume0.93 Prev Close0.79
Sales Surprise- EPS Surprise-17.54% Sales Q/Q- Earnings- Avg Volume150.66K Price0.75
SMA20-26.68% SMA50-32.04% SMA200-68.31% Trades Volume140,512 Change-4.45%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Resumed ROTH Capital Buy $14
Jul-22-24 08:00AM
May-21-24 09:52PM
Apr-22-24 08:56AM
Apr-19-24 04:30PM
Apr-16-24 11:52PM
08:30AM Loading…
Mar-06-24 08:30AM
Feb-16-24 08:00AM
Jan-03-24 05:15PM
Dec-07-23 08:00AM
Nov-28-23 04:15PM
Nov-13-23 04:05PM
Nov-10-23 08:50AM
Oct-25-23 08:30AM
Sep-29-23 08:00AM
Sep-21-23 04:05PM
08:00AM Loading…
Sep-19-23 09:00AM
Sep-18-23 11:01AM
Sep-14-23 08:45AM
Sep-06-23 04:30PM
Jun-15-23 04:45PM
May-24-23 04:45PM
May-22-23 07:00AM
May-19-23 04:05PM
May-10-23 11:15AM
Apr-17-23 04:15PM
Mar-30-23 08:45AM
Mar-16-23 04:10PM
Mar-02-23 04:15PM
09:15AM Loading…
Feb-09-23 04:15PM
Jan-18-23 09:15AM
Jan-10-23 04:15PM
Jan-09-23 08:00AM
Jan-05-23 04:15PM
Dec-05-22 04:30PM
Nov-07-22 08:00AM
Nov-04-22 08:30AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Oct-20-22 04:30PM
Oct-19-22 08:00AM
Sep-26-22 05:00PM
Sep-14-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Aug-31-22 08:00AM
Jul-22-22 04:15PM
Jul-04-22 10:23AM
Jun-28-22 08:30AM
Jun-24-22 04:15PM
Jun-20-22 08:00AM
Jun-15-22 08:00AM
Jun-14-22 08:00AM
May-31-22 04:30PM
May-27-22 08:54AM
May-03-22 08:00AM
Mar-07-22 08:00AM
Feb-15-22 08:00AM
Feb-14-22 08:00AM
Jan-26-22 08:00AM
Jan-12-22 08:00AM
Jan-06-22 04:15PM
Jan-05-22 04:30PM
Dec-21-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:45AM
Nov-10-21 08:00AM
Nov-04-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Sep-29-21 09:00AM
Sep-13-21 08:00AM
Sep-10-21 04:05PM
Aug-15-21 05:50AM
Jul-23-21 04:40PM
Jul-13-21 08:00AM
Jun-25-21 04:30PM
Jun-09-21 07:45AM
May-16-21 05:10AM
May-06-21 07:45AM
Apr-29-21 09:50AM
Mar-23-21 07:15AM
Mar-22-21 04:30PM
Mar-11-21 07:30AM
Feb-18-21 04:30PM
Feb-16-21 06:45AM
Feb-12-21 04:45PM
Feb-10-21 07:30AM
Feb-09-21 04:30PM
Feb-05-21 02:00AM
Jan-29-21 03:07PM
Jan-05-21 08:00AM
Dec-29-20 04:15PM
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorNov 27 '23Buy3.052,5007,6259,501Nov 28 06:55 AM
Wijngaard PeterDirectorNov 24 '23Buy3.092,5007,7257,001Nov 28 06:55 AM
Wijngaard PeterDirectorSep 19 '23Buy5.641,0005,6404,501Sep 20 11:27 AM
Foster Robert TCEO and DirectorSep 18 '23Buy5.601,6008,96050,470Sep 19 09:01 AM
Wijngaard PeterDirectorSep 15 '23Buy5.602,00011,2013,501Sep 20 11:27 AM
Foster Robert TCEO,CSO and DirectorSep 15 '23Buy5.401,6008,64048,870Sep 18 08:00 AM